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ACTIVE MANAGEMENT OF IRON DEFICIENCY ANEMIA IN PATIENTS 
WITH INFLAMMATORY BOWEL DISEASE 
 
CHRISTOPHER LYONS 
ABSTRACT 
Iron deficiency anemia (IDA) is a common extra-intestinal manifestation of 
inflammatory bowel disease (IBD).  It is particularly common in the pediatric population, 
with 40-60% of pediatric patients with IBD meeting criteria for anemia (Aljomah et al, 
2018). A number of studies have examined the use of both IV and oral iron treatments to 
treat anemia in IBD, but few have examined the safety and efficacy of these treatments in 
children and how they impact a patient’s health-related quality of life. We conducted a 
prospective cohort study of 79 pediatric patients admitted to Boston Children’s Hospital 
for management of their IBD. 48 of these patients received IV iron, 13 received oral iron, 
and 12 were not treated with either. Treatment with IV iron resulted in a statistically 
significant increase in hemoglobin of 1.75g/dL+/-1.4g/dL (mean +/- SD) from admission 
to the time of their first post-discharge visit (p=0.0001). Prescription of oral iron at the 
time of discharge did not result in a significant increase in hemoglobin over the same 
interval (p=0.481). Though there was a positive trend, IV iron treatment did not result in 
a  significant change in health-related quality of life (HRQOL) measurements as 
measured by the IMPACT-III questionnaire (p=0.06). Our study suggests that IDA is 
common in patients admitted for management of their IBD, IV iron is more efficacious in 
raising hemoglobin, and that larger studies will be needed to more fully demonstrate the 
impact of effective iron repletion on overall quality of life in these patients. 
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INTRODUCTION 
Inflammatory Bowel Disease (IBD) 
 Inflammatory bowel disease (IBD) is an umbrella term for a group of chronic 
inflammatory diseases that affect the gastrointestinal tract. The two most common 
manifestations of IBD are Crohn disease (CD) and ulcerative colitis (UC), and these 
disorders are differentiated based on disease location and the extent of inflammation in 
the wall of the intestine (Fakhoury et al, 2014). CD is characterized by often-
discontinuous inflammation that can occur in any portion of the GI tract (Figure 1).  
Radiographically, CD can present as a transmural disease with wall thickening or 
stricturing and histology is characterized by the presence of non-necrotizing granulomas. 
In contrast, the inflammation observed in patients with UC typically begins in the rectum 
and extends proximally, in a contiguous fashion, to involve part or all of the large 
intestine (Guariso & Gasparetto, 2017). The histology of mucosal inflammation observed 
in patients with either UC or CD displays evidence of chronicity (e.g. mucin depletion, 
loss of crypt branching). Sections of the GI tract in both UC and CD also often display 
large numbers of neutrophils. The inflammation in UC is often confined to the mucosa 
itself, while in CD the inflammation tends to be transmural in nature (Journal of 
American Medical Association, 2014) (Figure 1). A third subtype of IBD, commonly 
referred to as indeterminate colitis (IC), is reserved for patients whose clinical, 
radiologic, and histologic findings preclude a conclusive distinction between UC or CD 
(Rosen et al, 2015). 
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 Although the exact biologic and genetic etiologies of IBD have not yet been full 
elucidated, several working hypotheses have been put forward to explain the seemingly 
numerous mechanisms that may explain a common clinical presentation characterized by 
abdominal pain, diarrhea, and the presence of blood in the stool. The “bacterial 
penetration cycle hypothesis” posits that slight changes in the gut microbiome can result 
in alterations in the permeability of the intestinal wall, increased translocation of bacteria 
and bacterial products across the epithelial lining of the intestine, and a subsequent 
aberrant activation of the adaptive immune response (Guariso and Gasparetto, 2017). 
This dysregulated immune activation results in a constitutive release of pro-inflammatory 
cytokines and molecules, which likely explains the chronic inflammatory response seen 
in patients with IBD, and why most IBD treatments are directed at attenuating the body’s 
inflammatory response. The influence of genetics in the pathogenesis of IBD has also 
been extensively studied, with several candidate genes being proposed as risk factors for 
the development of the disease. Zhang and Li discuss a number of genes that have been 
identified in genome-wide association studies (GWAS).  The nucleotide-binding 
oligomerization domain containing 2 (NOD2) was the first gene identified to confer 
susceptibility to CD. NOD2 is an intracellular toll-like receptor analogue involved in 
bacterial identification, the regulation of antigen presentation, and the modulation of both 
adaptive and innate immunities (Zhang & Li, 2014). NOD2 variants, as well as other 
candidate genes implicated in regulating the body’s immune response, may be important 
predictors of a patient’s response to a change in the gut microbiota and/or development of 
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IBD, and future research in this field will be important in identifying the potential links 
between a patient’s genetics and their likelihood of developing IBD over their lifetime. 
 A patient’s environment may serve as an important mediator for the risk of 
developing IBD.  In their review on IBD in the pediatric population, Rosen and 
colleagues point to several lines of evidence implicating environmental factors in the 
development of  IBD. Most compelling is the finding that the concordance of IBD in 
monozygotic twins is less than 50% for CD.  In addition, the incidence of IBD is less 
common in developing countries, and this discordance dissipates as countries adopt 
increasingly Western diets and lifestyles. Increased rates of caesarean delivery, lack of 
exposure to breast milk, and increased dietary fat intake are other plausible risk factors 
for development of IBD (Rosen et al, 2015). Despite the mounting evidence of the 
environment as a risk factor for developing IBD, more research into the pathogenesis and 
epidemiology is needed before a definitive paradigm explaining the apparent increased 
incidence of IBD can be more fully explained. 
 The onset of IBD typically begins in childhood and adolescence, with nearly 25% 
of patients being diagnosed within the first 2 decades of life. (Ye et al, 2015). Sykora and 
colleagues conducted a meta-analysis of one hundred forty studies regarding the onset of 
pediatric IBD and found that the highest annual incidence of CD was 13.9/100,000 in 
North America and 15.0/100,000 in Europe, which appears to be consistent with the 
“bacterial penetration cycle hypothesis”; that IBD is most common in developed 
countries like the U.S. (Sykora et al, 2018).  
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 Several measures currently exist that can be used clinically to assess the severity 
of IBD symptoms and to categorize disease progression. For CD, the most utilized 
measurement of disease activity is the Crohn Disease Activity Index (CDAI). This metric 
includes a combination of laboratory data, physical exam findings, and self-reported CD 
symptoms, The CDAI was originally validated by Hyams and colleagues in 1991 along 
with the modified Harvey-Bradshaw index, which includes subjective and exam data. 
(Hyams et al, 1991) (Table 2). There also exists a short CDAI (sCDAI) that is limited to a 
questionnaire that can be readily filled out by patients in an outpatient setting without the 
need for additional laboratory testing (Henao et al, 2015). For UC, a very commonly used 
index for disease activity is the Mayo Score, which consists of four main diagnostic 
scoring components: stool frequency, rectal bleeding, flexible sigmoidoscopic 
examination, and physician global assessment. A shortened version of the Mayo score 
omits the sigmoidoscopy and only includes the stool frequency, rectal bleeding, and 
physician global assessment portions of the metric (Bewtra et al, 2014).  
The Ulcerative Colitis Activity Index (UCAI), a similar disease index to the 
CDAI, is often used to assess disease severity in adult patients with UC, and it has been 
shown to be a useful indicator for predicting disease outcome and response to therapy 
(Gürel & Kiyici, 2005). 
Pediatric versions of the CDAI and UCAI (the PCDAI and PUCAI, respectively), 
are utilized to assess disease severity and response to therapy in pediatric patients with 
IBD (Table 1). The ability of the PUCAI to discriminate between patients in clinical 
remission and those with mild to moderate disease, as well as the test-retest reliability, 
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was assessed by Dotson and colleagues in 2015 in comparison to physician global 
assessment (PGA) and found to be a reliable measure of UC disease activity in children 
with IBD (Dotson et al, 2015). Multiple versions of the PCDAI currently exist, and at the 
moment there does not seem to be any current consensus on which version is the most 
predictive of disease progression. Turner and colleagues conducted a comparison of the 
four major versions of the PCDAI including the PCDAI, the weighted PCDAI, the 
abbreviated PCDAI, and the short PCDAI.  They found the weighted PCDAI and 
standard PCDAI scores to be superior to the abbreviated PCDAI metrics as well as 
standard serologic biochemical testing.  However, both serologic and PCDAI assessment  
correlated poorly with fecal calprotectin, a protein often released by neutrophils into the 
GI tract during periods of extensive inflammation (Turner et al, 2007). A comparison of 
PUCAI and PCDAI scoring was utilized in the current study to track disease progression 
in study subjects. Measurements were obtained while patients were on the inpatient GI 
service and then again at the time of their first post-discharge ambulatory visit.    
Iron 
Iron is considered an essential micronutrient for the human body, and it has been 
shown to be involved in a number of essential biochemical and physiological processes. 
Iron’s most studied role is in oxygen transport through the blood, and it is an essential 
component of the oxygen binding portion of the heme protein. Iron also has important 
roles in the oxidation-reduction reactions of the electron transport chain and as a co-
factor for a number of enzymes (Abbaspour, Hurrell & Kelishadi, 2014). As a result of its 
physiological importance and the fact that no efficient excretory system for iron exists in 
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mammals, the absorption and recycling of the body’s iron stores is a tightly-regulated 
process, with several independent mechanisms existing at the transcriptional and 
translational level to finely tune the absorption of iron from the lumen of the gut (Figure 
2). 
Dietary iron can broadly be split into heme and non-heme iron, with heme iron 
being found mainly in animal products and non-heme iron being found in both animal 
and plant products. Dietary non-heme iron has been extensively studied, and much of our 
current understanding of intestinal iron absorption and regulation is derived from this 
form of iron. Dietary non-heme iron largely exists in the Fe3+ form, which must first be 
reduced to Fe2+ by ferrireductase enzymes found along the brush border of enterocytes 
prior to absorption. Once iron has been reduced to its Fe2+ form, it can be moved into the 
enterocyte through the divalent metal-ion transporter (DMT-1), which uses a proton 
gradient to help drive the movement of Fe2+ into the enterocyte. Once inside the 
enterocyte, the fate of intracellular iron is largely dependent on the current amount of iron 
that is being stored within the cell. During high iron conditions, dietary iron can be stored 
complexed with ferritin, an intracellular iron storage protein.  
 When the body’s iron needs are low, ferritin-complexed iron is trapped within the 
cell and lost into the stool during the normal turnover/sloughing of intestinal epithelial 
cells. During conditions of enhanced iron need (e.g. pregnancy, tissue hypoxia, blood 
loss), intracellular iron can be shuttled across the enterocyte with the aid of the 
intracellular chaperone ferroportin-1. This transport protein can facilitate  the movement 
of Fe2+ out of the enterocyte, where it is oxidized back to its Fe3+ state, and travels in 
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circulation bound to transferrin. Hepcidin is a liver-derived circulating peptide hormone 
that downregulates the availability of ferroportin transporters in the basolateral membrane 
by redirecting their transport and degradation within enterocyte lysosomes. Circulating 
hepcidin levels, in turn, are tightly regulated by ambient iron stores which can either be 
upregulated or downregulated in the blood depending on the body’s iron needs (Gulec, 
Anderson & Collins, 2014).  
 When the body’s iron stores and plasma hemoglobin level fall below normal 
values, complications from anemia can begin to manifest. Broadly speaking, anemia can 
be defined as a hemoglobin (Hb) concentration below thresholds established for specified 
populations living at sea level (Northrop-Clewes & Thurnam, 2013). The World Health 
Organization (WHO) has specified 6 populations when diagnosing anemia (Table 3), and 
each population’s hemoglobin cut-off value varies slightly (WHO, 2011). In the U.S. it is 
estimated that 5.6% of the population meets the WHO cut-off for anemia, with 1.5% 
meeting the threshold for moderate-severe anemia (Le, 2016). Anemia is often a 
significant predictor of poor health, so the identification and treatment of individuals at 
risk for developing anemia is of great importance with respect to public health. 
Iron Deficiency Anemia in IBD 
One of the most common extra-intestinal manifestations of IBD, particularly in 
pediatric populations, is iron-deficiency anemia (IDA). A study done by Aljomah and 
colleagues found that at the time of diagnosis 67.31% of CD patients met the WHO 
criteria for anemia, and that almost one-third of these patients (28.85%) had anemia 
attributable to iron deficiency (Aljomah et al, 2018). A similar study by Erikkson and 
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colleagues found that 36% of IBD patients met criteria for anemia.  They further noted 
that CD patients not only had a significantly higher incidence of anemia than their 
counterparts with UC, but that the anemia in patients with  CD was typically more 
refractory to therapy (Eriksson et al, 2018). 
 Although IDA in IBD can result from a number of complications associated with 
the disease phenotype, the most common explanation for anemia in patients with IBD is 
blood loss from the chronically inflamed intestinal mucosa in combination with decreased 
iron uptake into the enterocyte. Other contributing factors that may play a role include 
medication-induced decreases in erythrocyte production and the lysing of red blood cells 
in circulation. The diagnosis for IDA in patients with IBD is normally made after routine 
blood draws, when blood counts, hemoglobin, and mean corpuscular volume (MCV), as 
well as serum iron and ferritin,  can be used to make an diagnosis (Table 4). Symptoms of 
IDA in IBD are largely dependent on the severity of anemia, but more common 
complications include fatigue, pallor, dyspnea and tachycardia, which is due to decreased 
blood oxygen delivery to the periphery resulting in hypoxia. Symptoms not solely related 
to hematological function include hair loss, paresthesia in the hands and feet, and decreased 
cognitive abilities, all of which may contribute to decreases in quality of life for anemic 
patients (Kaitha, Bushir & Ali, 2015). 
 The most common approach to the treatment of IDA in IBD is iron 
supplementation, and this can be  accomplished using either oral or IV iron preparations 
(Kaitha, Bashir and Ali, 2015). The decision to use oral or IV iron is normally at the 
discretion of the patient and the provider, although data does exist that supports differing 
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efficacies of these two treatment choices. One well-studied drawback to oral iron 
supplementation are concerns that free iron in the intestinal lumen can lead to the creation 
of reactive oxygen species which can act to worsen inflammation in IBD (Papadopoulos 
et al, 2017). In contrast, the benefit of using oral iron to treat IDA is its relatively cheap 
cost compared to IV formulations and the fact that patients can continue to take oral iron 
supplements (e.g. ferrous sulfate) at home. However, a study by Lugg and colleagues 
found that only 30% of IBD patients experienced a return to normal Hb levels after a 
treatment regimen of oral iron tablets, with 51% of these patients experiencing side effect 
from the medication (Lugg et al, 2014). Despite it’s cost-effectiveness and ease of 
administration, the historically mixed improvement of anemia and potential for side-
effects makes the continued use of oral iron preparations dubious for the treatment of 
IDA in pediatric IBD. 
IV iron treatment, conversely, has the distinct advantage of delivering iron in a 
way that bypasses the lumen of the GI tract, with patients being able to receive larger 
doses of iron in a shorter amounts of time. Earlier IV preparations exposed patients to the 
risk of a potentially life-threatening hypersensitivity reaction.  Low molecular weight 
(LMW) iron dextran formulations have since been developed, and these preparations 
carry with them much less risk of a significant hypersensitivity reaction (Rampton et al, 
2014). A comparison of various IV iron formulations currently in clinical use is listed in 
Table 5. 
 Considerable research published in the last decade has established the efficacy of 
IV iron treatment for the correction of IDA in pediatric and adult patients with IBD. A 
 10 
study by Schroder and colleagues found that while patients that received oral and IV iron 
both had similar increases in serum hemoglobin, the IV iron group experienced a 
statistically significant increase in serum ferritin compared to the oral treatment group 
(Schroder et al, 2005). Similarly, Garcia-Lopez and colleagues conducted a prospective, 
observational study of 72 patients with IBD and found that high-dose IV iron treatments 
normalized serum ferritin and transferrin values in these patients, and that this effect was 
time-dependent such that a larger percentage of patients had normalized hematologic 
values at 12 weeks post-infusion compared to 2 weeks post-infusion (Garcia-Lopez et al, 
2016).  This evidence is consistent with similar findings supporting the notion that IV 
iron should replace oral iron treatment as the first-line therapy for significant IDA in 
patients with IBD, particularly for those patients hospitalized for management of active 
IBD.  Oral iron preparations are better suited for maintaining optimal iron levels in the 
ambulatory setting and after a patient is discharged from the hospital. 
Health-Related Quality of Life (HRQOL) Measurements 
Health-related quality of life (HRQOL) is an often-overlooked aspect of clinical 
care, and generally refers to an individual’s physical, psychological, social and emotional 
well-being and how these often overlapping dimensions can be affected by the presence 
of a chronic disease like IBD (Khanna & Tsevat, 2007). With the diagnosis of IBD often 
equated to a lifetime of waxing and waning symptoms, disease flare-ups may often 
correlate with worsening quality of life across multiple domains including a patient  
feeling like they have little control over their disease. Other factors such as extra-
intestinal symptoms, pharmacological and surgical treatments and their side effects, and 
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stress from the potential risk of cancer have also been found to negatively impact 
patient’s HRQOL (Habibi et al 2017). 
As such, the careful monitoring of HRQOL, particularly in pediatric patients, is of 
clinical importance both during the course of treatment and at subsequent follow-up 
visits. Anemia can adversely impact both physical growth and psychosocial development 
in younger IBD patients, and the added burden of fatigue from IDA can often result in 
poor social and emotional wellbeing in these patients. Several metrics have been 
designed to specifically address the concerns related to HRQOL in pediatric patients with 
IBD. The IMPACT-III is the third iteration of the IMPACT questionnaire, the first 
disease-specific HRQOL metric for pediatric IBD patients, and has proven to be a valid 
assessment of disease activy across multiple studies (Abdovic et al 2012; Werner et al 
2014). The IMPACT contains 35 questions grouped together into a number of domains 
designed to assess different areas of HRQOL, including bowel symptoms, emotional 
functioning, and social functioning, among others. It utilizes a 5-point Likert scale that 
ranges from “never/not at all” to “very much/very-often” depending on the nature of the 
question.  
The Pediatric Quality of Life Questionnaire (PedsQL) is a brief, standardized 
HRQOL metric that was designed to assess quality of life domains in pediatric patients 
suffering from a broad range of chronic illnesses, and as such is a more global assessment 
of HRQOL compared to the IMPACT-III (Varni et al 2003). For pediatric patients with 
IBD there exists a number of GI subscales including the Gastrointestinal Symptoms 
Module and General Well-Being Scale that can give providers a more accurate glimpse 
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of how the patient’s IBD symptoms are affecting their quality of life (Varni et al, 2014). 
Similar to the IMPACT-III, patients report how often a given statement pertained to them 
in last month (e.g. “I was happy, I feel good about myself”) and they are subsequently 
asked to rate this response on a Likert scale from 0 (never) to 4 (almost always). Answers 
to these questions are reverse scored with higher scores indicating a better quality of life.  
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SPECIFIC AIMS AND GOALS OF THE CURRENT RESEARCH 
The goal of the current research project is to expand upon prior work to better 
understand the risks and benefits related to oral and IV iron preparations in the treatment 
of iron-deficiency anemia in pediatric patients with IBD. Specifically, the current 
research will seek to assess the efficacy of both parenteral and enteral iron treatments to 
determine which preparations are most effective in bringing about a significant increase 
in hemoglobin, defined as a 2 or more-point increase. We hypothesize that, given the 
current evidence in the literature, IV iron would produce a significant increase in 
hemoglobin in pediatric IBD patients with IDA compared to oral iron formulations. We 
further hypothesize that iron treatment will produce significant improvements in quality 
of life in pediatric IBD patients as measured by a statistically significant increase in 
IMPACT-III scores from baseline to follow-up. Additionally, the safety of each treatment 
type will be examined in both the short and long-term to ensure that side-effects from 
iron treatment are largely minimized. 
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MATERIALS AND METHODS 
Study Design 
 The current study employed a prospective cohort design. Pediatric patients with 
IBD admitted to the inpatient GI service were screened for eligibility in the interval 
between 07/19/2018 and 03/01/2019. Inclusion criteria included patients with either an 
existing diagnosis of UC or CD or those with a new one at the time of admission.  
Additional criteria included a low hemoglobin level (adjusted for age and gender) and 
iron deficiency defined as a reticulocyte hemoglobin less than 27pg/dL. A hemoglobin of 
less than 12g/dL was used as a general rule-of-thumb to ask for the collection of 
additional iron studies from the patient’s GI attending physician. Patients were excluded 
from the study if: 
• they did not have a diagnosis of IBD 
• had a prior surgical history (including colectomy, ileostomy or small bowel 
resection),  
• had primary GI providers that did not recommend iron treatment to correct the 
anemia,  
• if the patient’s reticulocyte hemoglobin was greater than 27pg and/or a 
hemoglobin greater than 12g/dL or if the patient had an active infection.  
Patient Identification and Selection 
 The  Boston Children’s Hospital’s electronic medical record system (Powerchart) 
was reviewed two to three times per day in an effort to identify eligible patients for the 
study. Patients were also identified for the study on inpatient rounds every morning, 
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where one member of the research team was present to round with the team and enroll 
eligible patients for a number of ongoing studies. Iron studies, including hemoglobin, 
reticulocyte hemoglobin, reticulocyte count, plasma iron, total iron binding capacity 
(TIBC) and ferritin were included in the initial screening as part of the standard of care 
for patients with IBD and potential IDA. Education was also provided to GI providers 
and pediatric house staff to make certain that they understood screening for IDA and how 
to appropriately employ parenteral or enteral iron treatments. Patients completed HRQOL 
questionnaires prior to iron treatment and then again at their first post-discharge 
ambulatory follow-up visit to the Boston or Waltham GI clinics. To maintain privacy, 
patients were approached and consented in their hospital rooms, and curtains were drawn 
if a patient was sharing the room with another GI inpatient. After patients were consented 
and the questionnaires had been obtained, patients were was given a unique study ID that 
was devoid of and any personal identifiers (name, MRN, etc.).  
Study Data 
 Data that was collected from the patient’s electronic medical record included 
name demographic information (e.g. name, date of birth, sex, race, ethnicity, etc.), IBD 
diagnosis and subtype, past and active medications, blood counts, chemistry panels, 
disease activity scores (PUCAI and PCDAI), prior surgeries and colonoscopy/endoscopy 
reports. Laboratory measures included white cell counts, liver panel, inflammatory 
markers (e.g. C-reactive protein CRP) and iron studies. The decision to treat the patient 
with oral or IV iron was also documented, and any patients that were discharged prior to 
receiving iron treatment despite evidence of IDA were included in the study as a control 
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group. Any patients receiving packed red blood cell transfusions were included in the 
study, but their demographic and outcome data was collected as a separate treatment 
group.  Any adverse events to iron therapy were documented. 
Data Collection 
 Case report forms (CRFs) were created using the Research Electronic Data 
Capture website (REDCap). REDCap allows users to build and manage large and 
elaborate data collection forms, and Boston Children’s Hospital maintains a separate  
REDCap server for ongoing research projects with data collected from Powerchart. The 
electronic CRF used in this study was  HIPAA-compliant and approved by the hospital’s 
institutional review board. There were eight domains of the CRF for the current study: 
demographic data, anthropomorphic measures, medications, labs, treatments decisions, 
colonoscopy report, PedsQL and IMPACT-III questionnaire data. There were also 3 
longitudinal time points where data was entered: admission, discharge, and first 
encounter. Although all eligible participants began the study as inpatients, not all of them 
were seen at their first encounter as inpatients. The data collected in the CRF serves as a 
comprehensive repository of information for both the current study and any future studies 
that may attempt to answer related questions about IDA in pediatric patients with IBD. 
See Appendix 3: REDCap Forms for a full list of REDCap questionnaires used to collect 
data for the current study. 
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RESULTS 
Cohort Demographics and Characteristics 
A total of seventy-three pediatric IBD patients were enrolled in the current study. 
A total of 170 patients were screened for eligibility. Of these 170 patients, 91 were 
excluded from the study due to normal or elevated hemoglobin values at admission. Of 
the remaining eligible patients, 79 were identified as iron deficient as determined by 
hemoglobin and iron values obtained shortly after admission. 6 patients were excluded 
from final analyses due to the lack of a follow-up appointment after their discharge from 
the hospital or not having a follow-up appointment within the specified data collection 
window. 12 patients who were identified as iron deficient but were not treated with oral 
or IV iron prior to discharge were used as a control group.  
67 patients were treated for their iron deficiency with either IV iron (N=48), oral 
ferrous sulfate (N=13) or a packed red blood cell transfusion (N=4). 2 patients were 
treated with both packed red blood cells and IV iron but for the purposes of the analyses 
were excluded from the final results in the case that their change in hemoglobin was 
artifactually high and could affect the results (Figure 3). The cohort for the study was 
54.4% male (N=43) and was primarily white (N=50, 68.5%). 42 patients had a diagnosis 
of CD (53.2%), 35 patients had a diagnosis of UC (44.3%) and 2 had a diagnosis of 
indeterminate colitis. (Table 6). The average time for the first follow-up visit after 
discharge was 30.4 days. Detailed descriptive statistics as well as treatment numbers are 
found in tables 6 and 7, respectively. 
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Average Iron Dose by Treatment 
 The dose of iron that each patient received during and after their hospital 
admission was calculated and recorded. An average iron dose for all three IV iron 
formulations was calculated as well as for oral iron treatments. For oral iron treatments, 
doses were calculated according to prescribed dose during admission and after discharge.  
The total amount of oral iron was calculated by multiplying the elemental iron dosage in 
milligrams by the number of days between discharge and first follow-up. The total 
amount of iron was then calculated as the amount of iron given during admission added 
to the total amount of iron taken after discharge before their first follow-up. The average 
dose of Infed, Venofer and Injectafer given in the current study was 1056mg, 272mg and 
659mg, respectively, while the average oral iron dose given in the current study was 
1990mg (Figure 4).  We do not have definitive compliance data for subjects treated with 
oral iron. 
Correction of Anemia with IV Iron, Oral Iron or No Treatment 
 The change in hemoglobin (between inpatient treatment and first outpatient visit) 
in patients who received IV iron, oral iron, or no iron treatment during their hospital stay 
was calculated. IV iron formulations most commonly given were Venofer (iron sucrose), 
INFeD (iron dextran) and Injectafer (ferric carboxymaltose). The only oral iron 
formulation used in the current study was ferrous sulfate. The mean change (+/- SD) in 
hemoglobin for patients treated with IV iron, oral iron or no treatment was 1.75g/dL+/-
1.4g/dL, 0.33g/dL +/-1.4g/dL and 0.66g/dL +/- 0.5g/dL, respectively.There was a 
statistically significant increase in hemoglobin levels from admission to first follow-up 
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for both the IV iron patients (P=0.0001) and the control group (P=0.00161) but not for 
the oral iron group (P=0.481). When comparing across treatment groups, there was a 
statistically significant increase in hemoglobin from admission to follow-up in the IV 
group compared to the oral group (P=0.0049) and when comparing the IV group to the no 
treatment group (P=0.018). The change in hemoglobin when comparing the oral iron 
group and the no treatment group was not significant (P=0.49) (Figure 5). 
Correction of Anemia with Various IV Iron Formulations 
 The next analysis conducted compared different IV iron formulations used by 
clinicians in the study and how they differentially affected the change in hemoglobin 
from admission to follow-up. The decision to use a particular formulation was completely 
at the discretion of the treating physician in the study. The mean change (+/- SD) in 
hemoglobin for patients treated with Injectafer, Infed and Venofer was 2.58g/dL +/-
1.7g/dL, 1.86g/dL +/-1.3g/dL and 1.1g/dL +/- 1.1g/dL, respectively. Injectafer 
(P=0.0001), Infed (P=0.00006) and Venofer (P=0.00056) all resulted in statistically 
significant increases in hemoglobin from admission to follow-up for patients treated with 
IV iron. The only significant difference between the efficacy of the IV iron formulations 
occurred between Venofer and Injectafer, with Injectafer resulting in a statistically 
significant increase in hemoglobin compared to Venofer (P=0.005) (Figure 6). 
Changes in HRQOL Pre and Post Iron Treatment 
 The final analysis assessed whether any health-related quality of life 
measurements were significantly impacted by the administration of iron treatment in 
anemic pediatric patients with IBD. Patients were administered the IMPACT-III 
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questionnaire prior to being treated with IV or oral iron and then given the same 
questionnaire at their first follow-up visit. A higher score on the IMPACT-III is 
indicative of a higher quality of life compared to lower scores. A total of 12 patients 
completed baseline and follow-up IMPACT-III forms and all were treated with IV iron. 
The average IMPACT-III score at baseline was 126.25 and the average score at follow-up 
was 134.8. Despite the positive trend, this difference fell just short of reaching statistical 
significance (P=0.06) (Figure 7). 
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DISCUSSION 
 IBD is a chronic inflammatory process primarily affecting the GI tract.  However, 
the pathology underlying this disorder can have an adverse impact upon organs and 
systems that reside outside of the gut. The most common extra-intestinal presentation 
observed in patients with IBD, and particularly within the pediatric population, is iron-
deficiency anemia. Moreover, the developing bodies and brains of children make them 
disproportionately vulnerable to the effects of  IDA and this can lead to symptoms 
including fatigue, headache, cognitive impairment, dizziness, and shortened attention 
spans (Thayu & Mamula, 2005). Ameliorating these symptoms, along with the other 
biological effects of IDA, by addressing iron deficiency should be a major concern for 
any physicians treating pediatric patients with IBD. The purpose of the current study was 
to evaluate the efficacy and safety of IV and oral iron in treating iron deficiency anemia 
in a cohort of pediatric patients with IBD at Boston Children’s Hospital from 07/19/2018 
to 03/01/2019.  
 The main outcome of interest for the current study was an increase in circulating 
hemoglobin from admission to first follow-up.  We defined a hemoglobin change of 
2g/dL as significant and a hemoglobin value above 12g/dL as normal. Patients given IV 
iron during their admission had an average increase in hemoglobin of 1.75g/dL.  
Although this level falls below 2g/dL, the improvement of hemoglobin in IV iron treated 
patients was significantly better than those observed in patients in the no treatment group 
(0.66g/dL; P=0.018) or those treated with oral iron therapy (0.33g/dL; P=0.0049) (Figure 
6) . Nonetheless, any comparison of outcome should be interpreted with caution due to 
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the fact that the doses of iron both within and across treatment groups was not the same. 
The goal of IV iron infusions is rapid repletion of hemoglobin in a short time window. 
For example, iron sucrose (Venofer) is often used to treat anemia in patients with IDA.  
The product inserts recommends that infusions be administered at a dose no greater than 
0.5mg/kg (“Venofer: Dosage and Administration” 2016). The average dose of Venofer 
administered to patients in the current study was 272mg, and a number of patients were 
given multiple doses of Venofer during their hospital admission. Low-molecular weight 
iron preparations (including Infed), conversely have a much broader dosing range (up to 
2,000mg/infusion).  For this reason, patients in this study treated with Infed were 
administered an averge dose of iron of 1056mg. As such, the infusion time and dosing of 
the different IV iron formulations must be taken into account when interpreting the 
relative hemoglobin response. Our results indicate that while all three IV iron 
formulations resulted in statistically significant increases in hemoglobin from admission 
to follow-up, Injectafer had the highest average change in hemoglobin with 2.58g/dL 
compared to Infed and Venofer. Interestingly the average administered dose (659mg) for 
Injecter in this study falls between that of Venofer and Infed. These results could be due 
to a number of circumstances, including the particular pharmacokinetics and 
bioavailability ot discrete iron formulations, degree of inflammation present at time of the 
infusion, as well as differences in gender, height, and weight across subjects. Nontheless, 
the results of the current study further demonstrate the safety and efficacy of IV iron for 
use in pediatric patients with IBD and IDA. 
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 Oral ferrous sulfate is an often-used iron replacement therapy for IDA in pediatric 
patients with IBD, particularly in cases of mild anemia and when physicians would like 
to maintain iron levels over an extended period of time in the most cost-effective manner. 
In the current study, 13 patients were either treated with ferrous sulfate solely during their 
admission or were treated with ferrous sulfate during their admission and then after 
discharge. Patients discharged on oral ferrous sulfate therapy are typically prescribed 
preparations that contain anywhere from 50-65mg of elemental iron.  Patients are 
instructed to take these tablets once or twice per day with meals. This total oral intake of 
elemental iron between discharge and follow-up in these patients could exceed 2000mg. 
However, most of these patients did not manifest a significant increase in their 
hemoglobin levels between discharge and ambulatory follow-up (P=0.481) (Figure 5). A 
number of factors may explain these results. First, previous investigators, including 
Harrington and colleagues, demonstrated that the bioavailability of ferrous sulfate in a 
cohort of non-anemic Mexican children was only 5.9%.  It is possible that there exists a 
“first-pass effect” that lowers the systemic bioavailability of oral iron compounds due to 
its metabolism into inactive compounds by the liver (Bhosle et al 2017, Harrington et al, 
2011). As such, ferrous sulfate may be metabolized to inactive compounds by the liver 
before it is able to reach the systemic circulation where it can be incorporated into the 
heme moiety of hemoglobin in the hematopoetic cells of the bone marrow.  
 Patients with active inflammation from IBD may experience reduced iron 
absorption in the GI lumen that can also lead to lower circulating hemoglobin levels. 
Proinflammatory cytokines precipitate an increase in the circulating levels of the 
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regulatory hormone hepcidin, which is responsible for degrading the transporter 
necessary to move iron across the basolateral membrane of GI intestinal cells into 
circulation. It is thought that this response has evolved as a protective mechanism to limit 
the availability of iron to pathogens that have translocated into the systemic circulation.  
In contrast to self-limited bacterial and viral challenges, chronic idiopathic or 
autoimmune inflammation can significantly impact on enteral iron absorption leading to 
iron deficiency anemia (Hurell 2015). This may explain the current finding that patients 
treated with oral iron (either during admission or after discharge) in this study 
demonstrated blunted hemoglobin responses. In contrast, IV iron bypasses physiologic 
regulation at the level of the small bowel mucosa and is essentially 100% bioavailable 
and ready for use. 
 Anemic pediatric patients with IBD not treated with either oral or IV iron during 
their admission were used as a control group for the current study. Interestingly, there 
was a statistically signicant change in the hemoglobin levels in these patients from 
discharge to ambulatory follow-up (P=0.00161). There could be a number of reasons why 
we observed these results. The study design did not include longitudinal follow-up for 
untreated patients. As such, some of these patients may have engaged in behaviors at 
home that could have contributed to the rise in their hemoglobin level. This could have 
included taking a multivitamin containing iron or eating iron-enriched food including red 
meats. Future studies comparing iron treatments with a control group should include 
study parameters standardizing at home behaviors to control for potential dietary 
confounders. 
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 A secondary aim of the current study was to compare the health-related quality of 
life measurements of patients receiving iron treatment both before and after their iron 
repletion. For the current study, these HRQOL factors were assessed using the IMPACT-
III, a validated and widely used questionnaire to assess quality of life in pediatric IBD 
patients. Scores on the IMPACT-III can range from 35 to 175, with higher scores 
reflecting higher self-reported quality of life. There was no significant change in 
IMPACT-III scores between admission and follow-up in the treated and untreated study 
groups (P=0.06).  This could be due in part to the fact that only 12 patients completed 
both entry and exit IMPACT-III metrics.  The low sample size likely did not have 
sufficient  power to detect a significant change in IMPACT-III scores. All 12 patients 
were treated with IV iron, and this meant that we could not compare changes in scores 
with the oral iron group. In many cases, potential study subjects  missed completing their 
intial questionnaires because we were unable to provide them with the first study metric 
prior to initiating iron treatment. We would anticipate that successful iron repletion 
should result in an alleviation of  some of the systemic symptoms of IDA, including  
fatigue and dizziness, and a subsequent increase in IMPACT-III scores.  Although most 
of the patients in the current study displayed higher scores on the IMPACT-III at 
discharge compared to their scores at admission, future studies will be needed to better 
discern if adequate iron repletion and resolution of IDA can bring about a statistical or 
clinicallymeaningful improvement in health related quality of life in pediatric patients 
with IBD.   
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 The current study had a number of limitations. Patients discharged from the 
hospital were not protocolized to any uniform time-span in scheduling their first follow-
up appointment. As such, patients had a variable number of days before their follow-up 
and the collection of hematologic and HRQOL metrics. The average number of days to 
follow-up for the study was 30.4 days, but a few patients were not seen again in the clinic 
for well over a month and a half. This temporal variability in follow-up could influence a 
number of our outcome variables, as the pharmacokinetics of oral and IV iron vary 
considerably. Future studies should  assess enrolled patient’s hemoglobin and iron values 
after a specified number of days such that a comparison of the effect of oral and IV iron 
repletion can be analyzed and appreciated in the absence of a confounding time variable. 
 Another major limitation to the current study was the limited variability in the 
demographics of the cohort. Our study population was primarily white and male, and any 
study relyingon the metabolism of a drug or compound must take into account the 
variability of these processes as a factor of dynamic variables including age, ethnicity, 
and gender. Our cohort ranged in age from 3 to 18 years old, and with this range comes 
an inevitable inconsistency in absorption and metabolism rates. Gender differences may 
also account for some of the variability of iron absorption and metabolism observed in 
this study. It is been previously demonstrated  that gastric enzymes like alcohol 
dehydrogenase, as well as the pH of gastric juice, can vary between men and women, and 
these differences may result in significant differences in iron absorption and utilization 
for pediatric IBD patients with IDA (Soldin & Mattison, 2013). As such, future work on 
IDA in pediatric patients with IBD should better control for potential gender or age 
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confounders by enrolling a sufficiently large and diverse group to allow for the analysis 
of various sub-populations within the group. 
 In summary, iron deficiency anemia is a common and often debilitating 
complication of IBD, and its swift identification and treatment is of paramount 
importance when treating pediatric patients with IBD. Data from this study support the 
notion that  IV iron treatment is superior to both oral iron treatment and no treatment in 
increasing hemoglobin levels. Furthermore, although the results were not significant, data 
from this study suggest that iron repletion has the potential to improve the quality of life 
of pediatric patients with IDA. However, more work is needed to determine if IV or oral 
iron preparations are safer or more cost-effective in the long run  at improving the quality 
of life in these patients. The hope is that this study, as well as future research in this field, 
will continue to contribute to the growing body of literature surrounding the pathogenesis 
and management of pediatric patients with IBD and IDA. Ideally, these studies should 
contribute to the  goal of developing evidence-based standards to use in the rational 
treatement of iron deficiency anemia in this vulnerable population. 
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APPENDIX 1: FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Diagnostic and anatomical characteristics of UC and CD. Adapted from 
“Inflammatory Bowel Disease”, Journal of the American Medical Association, 2014. 
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Figure 2. General mechanism of heme and non-heme iron absorption from intestinal  
enterocytes. DMT-1=divalent metal-ion transporter; FPN1=ferroportin. Adapted from 
Gulec, Anderson and Collins (2014).  
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Figure 3. Flowchart of patient recruitment and eligibility. 
 
 
 
 
 
 
 
 
  
 
 
 31 
 
Figure 4. Average iron dose for each treatment option in milligrams. Error bars show one 
standard error above the mean for each treatment. The number of participants in each 
treatment group is shown.   
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Figure 5. Change in hemoglobin from admission to first encounter by treatment type. 
The number of participants in each treatment group is shown. ** represents a significant 
difference at p<0.05. N.S. represents a non-significant difference at p<0.05. None/Oral: 
P=0.49. None/IV: P=0.018. IV/Oral: P=0.0049.  
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Figure 6. Change in hemoglobin from admission to first encounter by IV irom 
formulation. ** represents a significant difference at p<0.05. N.S. represents a non-
significant difference at p<0.05. Infed/Injectafer: P=0.102. Infed/Venofer: P=0.74. 
Infectafer/Venofer: P=0.005.  
 34 
  
Figure 7. Change in IMPACT-III questionnaire score from baseline to first follow-up. 
N.S. represents a non-significant difference at p<0.05. P=0.06.  
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APPENDIX 2: TABLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.Pediatric Ulcerative Colitis Index (PUCAI). Adapted from Turner et al, 2007.  
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Table 2. Modified Harvey-Bradshaw Index of the Pediatric Crohn Disease Activity Index 
(PCDAI). Adapted from Hyams et al, 1991. 
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Table 3. The World Health Organization’s cut-offs for circulating hemoglobin to 
diagnose anemia in various populations. Hemoglobin values are reported in grams/liter. 
Adapted from WHO, Haemoglobin concentrations for the diagnosis of anemia and 
assessment of severity, 2011.  
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Table 4. Common laboratory measures and their relative increase or decrease from 
normal values when diagnosing IDA in IBD. ACD=anemia of chronic disease. 
MCV=mean corpuscular volume. sTfR=serum transferrin receptor. Adapted from Kaitha, 
Bashir & Ali, 2015.  
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Table 5. Comparison of the different available intravenous iron formulations used to treat 
IDA in IBD. Iron dextran (LMW)=Infed. Iron sucrose=Venofer. Iron 
carboxymaltose=Injectafer.  
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Table 6. Descriptive statistics for the current patient cohort (N=79). Unsure=diagnosis 
subtype was not clearly recorded on patient chart at the time of data collection.  
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Table 7. Treatment statistics for current patient cohort (N=79). 
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APPENDIX 3: REDCAP FORMS 
 
 
REDCAP 1: Demographic REDCap form (part 1). 
 
 
 43 
 
REDCAP 2: Demographic REDcap form (part 2). 
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REDCAP 3: Anthropomorphic measures RedCAP form. 
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REDCAP 4. Medication list REDCap form (part 1). 
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REDCAP 5. Medication list REDCap form (part 2). 
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REDCAP 6. Laboratory values REDCap form. 
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REDCAP 7. Hospital treatment decisions REDCap form. 
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REDCAP 8. Colonscopy report REDCap form. 
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REDCAP 9. PUCAI/abbreviated PCDAI REDCap form (part 1). 
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REDCAP 10. PUCAI/abbreviated PCDAI REDCap form (part 2). 
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REDCAP 11. PedsQL REDCap form (part 1). 
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REDCAP 12. PedsQL REDCap form (part 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54 
REDCAP 13. IMPACT-III REDCap form. The same form is used for outpatient follow-
up visits. 
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